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ABSTRACT 
Background/purpose: Bisphosphonates (BPs) are synthetic drugs with anti-tumour and bone 
antiresorptive activities. The use of BPs is suspected to favor the emergence of osteonecrosis of 
the jaw (ONJ), a putative side effect whose pathogenesis remains unclear. Thus, we aimed to get 
insights about the impact of BPs on osteoblasts functions, using a three-dimensional culture 
model, which is suggested to be more similar to the in vivo tissues than monolayers.  
Materials and methods: Effects of low (0.1 µM) and high (10 µM) concentrations  of zoledronic 
acid were investigated on osteoblasts (hFOB 1.19), cultured as multicellular spheroids (MCS). 
Proliferation, apoptosis, spheroid growth kinetics and morphology were studied using MTT and 
APH assays, Caspase 3 western-blotting, phase contrast imaging and scanning electron 
microscopy.  
Results: Proliferation, apoptosis and spheroid morphology showed that 10 µM ZA induced a 
significant reduction in the relative viable cell number, correlated with morphological alterations 
of spheroids and induction of apoptosis. On the opposite, lower ZA concentration (0.1 µM) 
promoted cell proliferation without affecting growth kinetics or spheroid morphology.  
Conclusion: ZA sensitivity of osteoblasts depends on concentration and experimental models. 
The dual dose-dependent effects of ZA on osteoblasts cultured as spheroids, thereby promoting 
or inhibiting cell proliferation, may provide opportunities in tissue engineering. At last, hFOB 
spheroid culture system represents a valuable model for the exploration of the molecular basis of 
BPs action on osteoblasts and for the development and evaluation of implantable biomaterials in 
bone site. 
 
Keywords: bisphosphonates (BPs), zoledronic acid (ZA), hFOB 1.19, multicellular spheroids 
(MCS), proliferation 
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INTRODUCTION 
Bisphosphonates (BPs) are synthetic compounds, both metabolically stable and structurally 
similar to inorganic pyrophosphate. They bind strongly to hydroxyapatite crystals and inhibit 
bone resorption by reducing physicochemical bone mineral dissolution and decreasing osteoclast 
activity. Due to their antiresorptive properties, these drugs are widely used in the clinical 
treatment of bone diseases with increased bone resorption such as post-menopausal osteoporosis, 
Paget’s disease or lytic bone metastasis. (1) BPs can be divided into two groups depending on 
their molecular mechanism of action at the cellular level. (2) Simple BPs, such as clodronate and 
etidronate, are metabolized intracellularly to non-hydrolysable analogues of ATP. The 
accumulation of these metabolites in the cytosol of osteoclasts induces cell death, probably by 
inhibiting ATP-dependent intracellular enzymes. (3,4) The more potent amino-BPs (e.g., 
zoledronic acid (ZA), alendronate and ibandronate), which are not metabolized, alter osteoclast 
function by inhibiting enzymes of the mevalonate biosynthetic pathway, notably the farnesyl 
diphosphate synthase (FPPS). Inhibition of FPPS leads to depletion of the metabolites FPP and 
geranylgeranyl diphosphate necessary for the post-translational modification (prenylation) of 
small GTPases, thereby affecting subcellular localization and function of these signaling proteins 
essential for osteoclast survival and activity. (5)  
BPs use has been linked to osteonecrosis of the jaw (ONJ), particularly in patients after 
intravenous therapy in the setting of malignancy. BPs-Related ONJ (BRONJ) can be caused by 
oral trauma or dental extraction, but it can also occur spontaneously. (6,7) Although causality 
between BPs exposure and ONJ is still controversial, a clinical staging system of BRONJ has 
been developed to more appropriately diagnose and clinically manage patients, ranging from 
stage 0 (no clinical evidence of necrotic bone, but non-specific clinical findings and symptoms) 
to stage 3 (exposed necrotic bone with pain, infection, pathologic fracture, extra oral fistula, oral 
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antral/oral nasal communication…). (8) Various hypotheses have been put forward to explain 
BRONJ pathophysiology, which is likely to be multifactorial. It is postulated that BRONJ 
localizes on the jaws because of the heavy bone turnover in this area, causing BPs to accumulate 
preferentially in jaws at cytotoxic concentrations. Pathophysiology may also involve suppression 
of bone turnover and angiogenesis, altered function of oral mucosal cells, microbial flora, anti-
inflammatory effects and genetic predispositions. (9) Beyond well-described direct effects of BPs 
on osteoclastic activity, significant clinical and experimental evidence indicates that BPs also 
influence osteoblast functions. (10,11) In vitro and in vivo studies demonstrated dose-dependent 
effects of BPs on cell proliferation, cell differentiation, apoptosis and matrix mineralization. High 
concentrations (> 10 µM) generally produce adverse effects on these processes that may account 
for the occurrence of BRONJ. (12-17) On the opposite, lower BPs concentrations act positively 
on osteoblastic function by promoting survival, proliferation and differentiation of bone-forming 
cells. (17-20) While this dual effect of BPs on osteoblasts is now well established, uncertainty 
remains concerning the threshold of cytotoxic and clinically relevant concentrations of BPs, 
probably because of multiple experimental models used for investigations. 
The objective of this in vitro study was to evaluate the effects of ZA − a commonly prescribed 
amino-BPs – on osteoblasts in a three-dimensional (3-D) culture system, namely multicellular 
spheroids (MCS). (21) The MCS model is based on the cell’s propensity to self-aggregate when 
cultured in non-adhesive conditions. By restoring cell-cell and cell-matrix interactions, this 3-D 
system more closely mimics living tissue than monolayer cultures do, (22,23) making MCS-
based assays more predictive of in vivo response to drugs. By examination of cell proliferation, 
cellular apoptosis and spheroid morphology after ZA treatment, we demonstrated that the dual 
dose-dependent effect of ZA already observed in monolayer culture is conserved in these 
osteoblastic microtissue-like cultures. 
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MATERIALS AND METHODS 
Cell culture 
The human fetal osteoblast cell line hFOB 1.19 (hFOB) was purchased from ATCC. hFOB cells 
were maintained in a 1:1 mixture of phenol red-free DMEM/Ham’s F-12 medium, supplemented 
with 10% fetal bovine serum, 100 IU/mL penicillin, 100 µg/mL streptomycin, 20 mM HEPES 
buffer, 2 mM L-glutamine and 300 µg/mL G418. For cell expansion, hFOB cells were incubated 
at 33.5 °C and 5% CO2 and fed twice a week. On reaching 80% confluency they were passaged 
using 0.05% trypsin-0.02% EDTA. 
Generation and culture of MCS 
Formation of hFOB spheroids was achieved using agarose-coated 96-well tissue culture plates 
(50 µL of 1.5% agarose in Phosphate-Buffered Saline (PBS). The seeding density was 2x103 cells 
per well. After 96 h of incubation, spheroid cultures were treated by replacing 50% (=100 µL) of 
supernatant with normal medium or medium supplemented with ZA (Zometa®, Novartis, East 
Hanover, NJ, USA) diluted in PBS at 2X final concentration. Half of the supernatant was 
replaced every 2 or 3 days with drug-free or drug-supplemented medium to ensure constant 
culture conditions. hFOB MCS were incubated at 33.5 °C for all experiments. 
MTT assay 
The relative growth of hFOB cells in monolayer was evaluated using the MTT (methyl-
tetrazolium salt; 3[4,5-dimethyl-thiazoyl-2yl] 2,5-diphenyl-tetrazolium bromide) assay as 
previously described.(24) Briefly, hFOB cells were seeded in 96-well tissue culture plates in 200 
µL medium per well. After 24 h, the cells were incubated with different ZA concentrations for 3 
and 10 days. hFOB cells were then exposed to MTT (1 mg/mL) for 3 h at 37 °C. After complete 
solubilization of formazan crystals in DMSO, optical density was measured on an ELISA plate 
reader at 570 nm. 
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APH assay 
The relative cell proliferation of hFOB in 3-D culture was evaluated after 3 days and 10 days in 
absence or presence of 0.1 or 10 µM ZA using the acid phosphatase assay (APH) as previously 
described. (25) Briefly, 10 spheroids from the same culture conditions were pooled, washed with 
PBS and transferred into a well of a 96-well microplate. The supernatant was discarded to a final 
volume of 100 µL. Then, 100 µL of the assay buffer (Immunopure p-nitrophenyl phosphate 
20 mg/10 mL, sodium acetate 0.1 M, Triton X100, 0.1%) was added to each well, and plates were 
incubated at 37 °C for 90 min. Following incubation, 10 µL of 1 N NaOH was supplemented to 
each well, and absorption at 405 nm was measured on an ELISA plate reader. 
Microscopy analyses 
Phase-contrast imaging of hFOB MCS was performed using an inverted microscope. Spheroids 
were assessed visually for differences in cell morphology from day 0 (i.e., 96 h after spheroid 
initiation) to day 14, in absence or presence of ZA. At least 48 MCS from each indicated time 
point were used to calculate the average diameter using Photoshop® software. In addition, hFOB 
MCS cultivated for 3 days or 10 days in drug-free or drug-supplemented medium were examined 
by scanning electron microscopy (SEM). Spheroids were rinsed twice in PBS and ﬁxed for 3 h 
with 2.5% glutaraldehyde in PBS. Then, samples were washed twice in PBS and dehydrated in 
graded alcohol (80°, 95° and 100°) and acetone. After critical drying point (CPD 010, Balzers 
Union, Balzers, Lichtenstein) using liquid carbon dioxide, samples were coated with a thin layer 
of gold-palladium and observed via SEM. 
Protein extraction and Western blot analysis 
After 3 or 10 days of ZA treatment, hFOB MCS were collected, rinsed twice in cold PBS and 
homogenized in cold RIPA protein extraction buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 2 mM EDTA). Homogenates were then sonicated, 
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incubated on ice for 30 min and centrifuged at 14,000 g for 15 min at 4 °C. Supernatants (total 
protein) and pellets (cellular debris) were collected and stored at -80 °C until use. Proteins were 
quantified with the Micro BCA™ Protein Assay Kit (Thermo Scientific, Waltham, MA USA), 
according to the manufacturer’s instructions. 20 µg of total proteins were separated by 
electrophoresis in a 10% polyacrylamide SDS gel and transferred onto a PVDF membrane 
(Millipore, Merck KGaA, Darmstadt, Germany). After saturation, membranes were incubated 
with rabbit monoclonal antibodies raised against cleaved caspase-3 or alpha-tubulin. HRP-
conjugated secondary antibodies were used subsequently before ECL signal detection. All 
antibodies were purchased from Cell Signaling Technology. 
Statistical analysis 
The data are expressed as means ± standard deviation (s.d.). All experiments were conducted in 
triplicate. Comparisons across multiple experimental groups were performed using a one-way 
analysis of variance (ANOVA) followed by PLSD Fisher test using StatView v5.0 software. The 
observed differences relative to a probability of P < 0.05 were considered significant. 
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RESULTS 
Effect of ZA on hFOB cell proliferation in monolayer and 3-D cultures 
To test whether the culture model influences ZA sensitivity of hFOB cells, a comparative study 
of relative cell growth between monolayer and spheroid cultures was carried out. 
Analysis of cell proliferation in hFOB monolayer culture was realized using MTT assay after 3 
days or 10 days culture with different ZA concentrations (Figure 1). Results are documented 
relative to the respective untreated control (set to 100%). Exposure of hFOB to 0.1 µM ZA did 
not alter cell proliferation when compared with control cells (101.7% ± 7.2% at day 3, 102.5% ± 
5.5% at day 10). In contrast, relative growth of hFOB cells in monolayer culture was significantly 
decreased after 3 days and 10 days in presence of 10 µM ZA, respectively to 87.4% ± 7.4% (P < 
0.0001) and 40.4% ± 9.7% (P < 0.0001) of untreated cells’ growth. 
To explore the sensitivity of hFOB cells to ZA treatment in 3-D cultures, the relative number of 
viable cells in hFOB MCS incubated in absence or presence of 0.1 or 10 µM ZA was determined 
using the APH assay (Figure 2) in comparison with respective untreated control (set to 100%). 
No significant difference was found between experimental conditions at day 3 (104.3% ± 9.9% 
for 0.1 µM, 94.2% ± 8.4% for 10 µM), whereas a lower relative viable cell number was observed 
after 10 days incubation in 10 µM ZA (80.4% ± 12.3%; P < 0.0001), in agreement with MTT 
assay results although growth inhibition appeared much more pronounced in monolayer cultures. 
On the other hand, 10 days treatment with 0.1 µM ZA seemed to promote slightly hFOB cell 
proliferation (114.5% ± 9.0%; P < 0.0001) only when cultured as MCS. 
Impact of ZA on hFOB MCS growth and morphology 
Monitoring of ZA effects on hFOB MCS growth and morphology was achieved through a 
combination of phase-contrast imaging and SEM analysis. Spheroid growth kinetics as 
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determined through MCS diameter measurement (Figure 3, Figure 4) revealed a very gradual and 
linear increase of mean spheroid size when cultured in absence of ZA, from 280 µm on day 0 to 
405 µm on day 14. A nearly identical growth curve was obtained with spheroids incubated with 
0.1 µM ZA, without any statistically significant difference in spheroid size at any time point. On 
the opposite, growth inhibition was evident for hFOB MCS treated with 10 µM ZA. Indeed, the 
diameter increase was almost totally abrogated as soon as 3 days culture, the difference in 
diameter being highly significant at day 7 (P < 0.0001) when compared with untreated MCS. 
Interestingly, spheroid size reached a stable plateau (around 290 µm) maintained for at least 14 
days of culture. To test whether ZA-induced growth inhibition of hFOB spheroid was correlated 
with morphological alterations, SEM analysis was carried out at 3 days or 10 days culture in 
drug-free or drug-supplemented medium (Figure 5). Microscopic examination of untreated 
spheroids after 3 or 10 days showed a compact spherical architecture without any distinguishable 
osteoblast − except for the round-shaped detaching ones − indicating an extremely dense cellular 
network. At high magnification (x3000), the surface of the MCS displayed filamentous 
structures, suggestive of cell membrane protrusions. SEM micrographs of spheroids treated with 
0.1 µM ZA for 3 or 10 days, or with 10 µM ZA for 3 days did not reveal any morphological 
difference with control spheroids. In contrast, the structural integrity of hFOB MCS incubated for 
10 days with 10 µM ZA appeared dramatically affected. Indeed, although spheroids conserved a 
spherical aspect, they were characterized by a highly irregular and grainy surface. 
Immunodetection of the active form of caspase-3 during ZA treatment 
Because exposure to the highest concentration of ZA compromised hFOB growth kinetics and 
morphology, we further examined whether the caspase cascade was triggered in response to ZA 
by performing Western blot analysis of cleaved caspase-3 (Figure 6). Immunodetection on total 
protein extracts from treated and untreated hFOB MCS revealed the presence of the active form 
 - 10 - 
of caspase-3 after 3 days incubation with 10 µM ZA. Moreover, no electrophoretic band was 
detected at day 10, indicating a transient activation of the apoptotic cascade. 
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DISCUSSION 
While BPs are widely used in clinical practice for their bone antiresorptive action, accumulating 
evidence demonstrates that osteoclasts are not the only direct cellular targets of BPs and that 
these drugs affect as well the activity of bone-forming osteoblastic cells. The findings that BPs 
modulate expression of RANKL (receptor activator of NF-kappaB ligand) and osteoprotegerin  in 
osteoblasts that may in turn indirectly interfere with differentiation and survival of osteoclasts 
highlight the complexity of BPs action on bone cells.(26,27) In this context, the clinical study of 
Recker and colleagues showing an increase of the mineral apposition rate in patients 
intravenously treated with ZA exemplifies the current view that BPs modulate both arms of bone 
remodelling. (28) However, the molecular mechanisms by which BPs regulate the activity of 
osteoblast is not completely understood. 
As exposed above, literature data indicate that high (micromolar) concentrations of BPs 
compromise viability and function of osteoblastic cells whereas lower concentrations stimulate 
osteoblast proliferation/differentiation and inhibit osteoblast/osteocyte apoptosis. In line with 
these observations, we demonstrated that ZA treatment of hFOB MCS induces positive or 
negative effects on osteoblasts in a dose-dependent manner. The highest concentration (10 µM) 
blocks cell proliferation, alters MCS morphology and induces apoptosis that might be partly 
responsible for the development of BRONJ, whereas the lowest (0.1 µM) promotes slightly but 
significantly cell growth. 
Our findings that 10 µM ZA inhibits the increase of MCS diameter after three days of incubation, 
and that the size of MCS remains constant the following days, suggest ZA exerts a cytostatic 
effect on osteoblasts, as already shown in other cell types. (29,30) The transient activation of 
caspase cascade may signify that ZA has a pro-apoptotic effect as well but only on some sensitive 
cells. To test whether ZA-induced growth inhibition was correlated with induction of bone-
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forming activities, von Kossa staining was performed but did not reveal any mineralized nodule 
(data not shown). We conclude that the non-proliferative state of hFOB cells is not associated 
with the differentiation process, in contrast with previous results obtained with hFOB monolayer 
cultures. (17,31) Further supporting the idea that 3-D MCS model presents specific properties 
conditioning the effect of ZA on osteoblastic cells, our results from MTT and APH assays 
showed that the anti-proliferative effect of high concentration of ZA is much more acute in 
monolayer than in MCS, suggesting a protective effect of the 3-D experimental condition. 
Emergence of a hypoxia-related mechanism of resistance inside the MCS may provide an 
explanation for this phenomenon, hypoxic conditions preventing the anti-proliferative and pro-
apoptotic effects of amino-BPs on osteoblast-like cells. (32) Alternatively, limited penetration 
and diffusion of ZA within the MCS may confine the pharmacological action of ZA to the cells 
located in the outermost layer of the spheroid, reducing consequently the proportion of cells 
exposed to ZA in comparison with monolayer cultures. Further studies would greatly benefit 
from fluorescently labeled conjugates of amino-BPs, which may provide useful information on 
the gradient distribution of these drugs within MCS as well as on the mechanisms of cellular 
uptake and potential transcytosis. (33,34) Conversely, we have described that 0.1 µM ZA 
moderately promotes cell growth of MCS. This anabolic effect on osteoblasts has been 
demonstrated for other amino-BPs and is thought to involve binding to and inhibition of protein 
tyrosine phosphatases. (35) However, why this proliferative effect is restricted to hFOB cells 
cultured as MCS remains to be solved. 
Our observation that the biological response to ZA not only depends on the concentration but also 
on the experimental model, as already proposed, (36) emphasizes the great potential of MCS 
model as microtissue-like model for drug evaluation. (37) Indeed, the restoration of cell-cell and 
cell-matrix interactions confers to the MCS model structural and functional properties 
 - 13 - 
physiologically more relevant than monolayer cultures, giving to MCS-based assays a better 
predictive value of in vivo drug efficacy. For these reasons, in cancer research, the MCS 
represents an incomparable system for drug screening and metastasis analysis, as an avascular 
tumor model reproducing the in vivo pathophysiology of tumor tissue. (37,38)  
Also, the MCS constitutes a highly valuable research tool for tissue engineering with multiple 
applications in regenerative medicine. For example, Kelm and colleagues have generated 
vascularized macrotissues by assembling individual MCS coated with endothelial cells, and 
observed that these macrotissues were connected to the host’s vascular system after in vivo 
implantation, illustrating the promising potential of heterotypic MCS as minimal building block 
for ex vivo generation of macrotissues. (39)  
Concerning the specific field of bone tissue engineering, multiple therapeutic strategies based on 
direct (coating, incorporation) or indirect (adjunct therapy) association of BPs with scaffolds 
(bioactive glasses, hydroxyapatite scaffolds, implants) have been developed. (40) These 
applications rely on the mechanical and putative osteoconductive and osteoinductive properties of 
bone substitutes, in conjunction with the local or systemic delivery of BPs, to promote bone 
regeneration. In this context, the hFOB spheroid culture system represents a convenient in vitro 
model for studying the effects of BPs on osteoblasts, and may greatly contribute to our 
understanding of their mechanisms of action on bone cells in the context of both tissue-
engineered bone regeneration and physiopathology of BRONJ. 
 
Based on the hFOB MCS model, this study shows that ZA exerts dual dose-dependent effects on 
osteoblast functions in 3-D cultures, inducing MCS growth arrest and apoptosis at micromolar 
concentration, but promoting cell proliferation at a lower level. Besides constituting a model of 
choice for elucidating the mechanisms of action of BPs on osteoblast, the hFOB MCS culture 
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system may also be very useful in assessing the effects of new bone substitutes on bone-forming 
cells and, more generally, in screening potential therapeutic molecules. Nevertheless, further 
studies are needed to improve the physiological relevance of the MCS model, for example 
through the development of heterotypic spheroids mixing osteoblasts and endothelial cells. Such 
experimental models may not only contribute to in vitro molecular and cellular studies but also 
have great applications in tissue engineering, especially as building blocks for tissue 
reconstruction with autologous cells. 
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FIGURE LEGENDS 
Figure 1. Relative cell growth of hFOB cells in 2-D culture. Relative growth of hFOB cells in 
monolayer culture was determined using a MTT assay after 3 days (D3) or 10 days (D10) of 
treatment with indicated concentrations of ZA. Number of viable cells is presented as percent of 
PBS-treated control spheroids (Ctrl), expressed as mean ± s.d. of triplicate experiments (**, P < 
0.0001 compared to control). 
 
Figure 2. Relative cell growth of hFOB cells in 3-D culture. Relative cell growth in hFOB 
MCS was determined using an APH assay following 3 days (D3) or 10 days (D10) of treatment 
with indicated concentrations of ZA. Results are presented as percent of APH activity in PBS-
treated control spheroids (Ctrl), expressed as mean ± s.d. of triplicate experiments (**, P < 
0.0001 compared to control). 
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Figure 3. Monitoring of hFOB MCS growth. Graph visualizes spheroid diameter evolution 
kinetics of hFOB MCS grown in absence of ZA (□) or incubated with 0.1 µM (∆) or 10 µM (●) 
ZA for up to 14 days. Data points are mean diameter ± s.d. from 48 individual spheroids (**, P < 
0.0001 compared to control). 
 
Figure 4. Phase-contrast imaging of hFOB MCS. Representative phase-contrast images of 
hFOB MCS are shown, illustrating the inhibitory effect of 10 µM ZA on spheroid growth. Scale 
bar, 100 µm. 
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Figure 5. Examination of hFOB MCS structural integrity by scanning electron microscopy 
(SEM). SEM micrographs of hFOB MCS incubated for 3 days (A, D, G) or 10 days (B, C, E, F, 
H, I) in absence or presence of indicated ZA concentrations are shown. C, F and I correspond to 
high-magnification (x3000) images of insets in B, E and H respectively. Scale bars, 10 µm. 
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Figure 6. Western blot analysis of cleaved caspase-3 in hFOB MCS upon treatment with 
ZA. Protein level of the active form of caspase-3 was investigated in control spheroids or 
spheroids exposed to 0.1 or 10 µM ZA during 3 or 10 days. Tubulin was used as a loading 
control. 
 
 
